- Results Expected in Fourth Quarter of 2008 -
MONTVALE, N.J., Sept. 26 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it has completed its Phase 1 multiple ascending dose study of R4996/MEM 63908 in healthy volunteers. The multiple ascending dose study is the fourth and final study in the Company's Phase 1 program for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7 receptor being developed in collaboration with Roche. Memory Pharmaceuticals expects to report top-line results from the entire Phase 1 program in the fourth quarter of 2008.
"We conducted a robust and comprehensive Phase 1 program for R4996/MEM 63908 during which over 100 volunteers took R4996/MEM 63908. The data from these studies will provide us and our partner Roche with important insights into the safety, dosing and appropriate development path for the compound," stated Stephen Murray, M.D., Ph.D., Chief Medical Officer of Memory Pharmaceuticals. "R4996/MEM 63908, the second compound in our nicotinic alpha-7 receptor program, has the potential to address serious cognitive disorders such as Alzheimer's disease, and we look forward to analyzing the data from these studies."
The Phase 1 program for R4996/MEM 63908 included four studies: a
randomized, double-blind, placebo-controlled single ascending dose study in
56 healthy adult male volunteers; a food interaction study in 12 healthy
adult male volunteers; a randomized, placebo-controlled single dose study
in 16 elderly male and female volunteers; and a randomized,
placebo-controlled multiple ascending dose study in 48 healthy volunteers,
which included 32 young males and females and 16 elderly males and females.
The studies were conducted in Montr
|SOURCE Memory Pharmaceuticals Corp.|
Copyright©2008 PR Newswire.
All rights reserved